ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms

Neuroendocrinology

Volumn 95, Issue 2, 2012, Pages 74-87

  Delle Fave, Gianfranco ^a   Kwekkeboom, Dik J ^b   Van Cutsem, Erik ^c   Rindi, Guido ^d   Kos Kudla, Beata ^e   Knigge, Ulrich ^f   Sasano, Hironobu ^g   Tomassetti, Paola ^h   Salazar, Ramon ⁱ   Ruszniewski, Philippe ^j  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b HÔPITAL LOUIS MOURIER   (France)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d CATHOLIC UNIVERSITY   (Italy)

^e MEDICAL UNIVERSITY OF SILESIA   (Poland)

^f Rigshospitalet   (Denmark)

^g TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^j BEAUJON HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; LUTETIUM 177; STREPTOZOCIN; YTTRIUM 90;

CANCER CLASSIFICATION; CANCER SURVIVAL; CLINICAL FEATURE; CONSENSUS; DUODENUM TUMOR; GASTROINTESTINAL TUMOR; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; IMAGING SYSTEM; NEUROENDOCRINE TUMOR; NONHUMAN; NUCLEAR MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR VOLUME;

DUODENAL NEOPLASMS; HUMANS; NEUROENDOCRINE TUMORS; STOMACH NEOPLASMS;

EID: 84857831429     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000335595     Document Type: Review

References (141)

1. Ruszniewski P, Delle Fave G, Cadiot G, Komminoth P, Chung D, Kos-Kudla B, et al: Welldifferentiated gastric tumors/carcinomas. Neuroendocrinology 2006; 84: 158-164.
2. Jensen RT, Rindi G, Arnold R, Lopes JM, Brandi ML, Bechstein WO, et al: Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas). Neuroendocrinology 2006; 84: 165-172. (Pubitemid 46361050)
3. Kloppel G, Perren A, Heitz PU: The gastroenteropancreatic neuroendocrine cell system and its tumors: The WHO classification. Ann NY Acad Sci 2004; 1014: 13-27. (Pubitemid 38594787)
4. Attanoos R, Williams GT: Epithelial and neuroendocrine tumors of the duodenum. Semin Diagn Pathol 1991; 8: 149-162.
5. Jensen RT, Doherty GM: Carcinoid tumors and the carcinoid syndrome; in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, Lippincott Williams & Wilkins, 2001, pp 1813-1833.
6. Hoffmann KM, Furukawa M, Jensen RT: Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol 2005; 19: 675-697. (Pubitemid 41614116)
7. Soga J, Yakuwa Y: Duodenal carcinoids: A statistical evaluation of 635 cases collected from the literature. J Exp Clin Cancer Res 1996; 15: 3-10. (Pubitemid 26132423)
8. Burke AP, Federspiel BH, Sobin LH, Shekitka KM, Helwig EB: Carcinoids of the duodenum. A histologic and immunohistochemical study of 65 tumors. Am J Surg Pathol 1989; 13: 828-837.
9. Niederle MB, Hackl M, Kaserer K, et al: Gastroenteropancreatic neuroendocrine tumours: The current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: An analysis based on prospectively collected parameters. Endocr Relat Cancer 2010; 17: 909-918.
10. Bordi C: Gastric carcinoids. Ital J Gastroenterol Hepatol 1999; 31(suppl 2):S94-S97. (Pubitemid 29527875)
11. Rindi G, Luinetti O, Cornaggia M, et al: Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: A clinicopathologic study. Gastroenterology 1993; 104: 994-1006. (Pubitemid 23090750)
12. Rindi G, Bordi C, Rappel S, et al: Gastric carcinoids and neuroendocrine carcinomas: Pathogenesis, pathology, and behavior. World J Surg 1996; 20: 168-172. (Pubitemid 26069482)
13. Borch K, Renvall H, Liedberg G: Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 1985; 88: 638-648. (Pubitemid 15130649)
14. Solcia E, Bordi C, Creutzfeldt W, et al: Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988; 41: 185-200. (Pubitemid 19070318)
15. Carney JA, Go VL, Fairbanks VF, et al: The syndrome of gastric argyrophil carcinoid tumors and nonantral gastric atrophy. Ann Intern Med 1983; 99: 761-766. (Pubitemid 14248401)
16. Bordi C, Yu JY, Baggi MT, et al: Gastric carcinoids and their precursor lesions. A histologic and immunohistochemical study of 23 cases. Cancer 1991; 67: 663-672.
17. Sjoblom SM, Sipponen P, Karonen SL, et al: Mucosal argyrophil endocrine cells in pernicious anaemia and upper gastrointestinal carcinoid tumours. J Clin Pathol 1989; 42: 371-377. (Pubitemid 19121582)
18. Stockbrugger RW, Menon GG, Beilby JO, et al: Gastroscopic screening in 80 patients with pernicious anaemia. Gut 1983; 24: 1141-1147. (Pubitemid 14205816)
19. Gough DB, Thompson GB, Crotty TB, et al: Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia. World J Surg 1994; 18: 473-480. (Pubitemid 24273843)
20. Rappel S, Altendorf-Hofmann A, Stolte M: Prognosis of gastric carcinoid tumours. Digestion 1995; 56: 455-462.
21. Modlin IM, Gilligan CJ, Lawton GP, et al: Gastric carcinoids. The Yale Experience. Arch Surg 1995; 130: 250-256.
22. Wilander E, El-Salhy M, Pitkanen P: Histopathology of gastric carcinoids: A survey of 42 cases. Histopathology 1984; 8: 183-193. (Pubitemid 14129002)
23. Thomas RM, Baybick JH, Elsayed AM, et al: Gastric carcinoids: An immunohistochemical and clinicopathologic study of 104 patients. Cancer 1994; 73: 2053-2058. (Pubitemid 24107957)
24. Cattan D, Roucayrol AM, Launay JM: Fundic endocrine disease of fundic atrophic gastritis with achlorhydria. I. Serum gastrin and fundic endocrine hyperplasia relationship: Reality and significance. Gastroenterol Clin Biol 1991; 15: 30C-35C.
25. Vannella L, Sbrozzi-Vanni A, Lahner E, et al: Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment Pharmacol Ther 2011; 33: 1361-1369.
26. Borch K, Ahren B, Ahlman H, et al: Gastric carcinoids: Biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005; 242: 64-73. (Pubitemid 40917969)
27. Marignani M, Delle Fave G, Mecarocci S, et al: High prevalence of atrophic body gastritis in patients with unexplained microcytic and macrocytic anemia. A prospective screening study. Am J Gastroenterol 1999; 94: 766-772. (Pubitemid 29124879)
28. Merola E, Sbrozzi-Vanni A, Panzuto F, et al: Type I gastric carcinoids: A prospective study on endoscopic management and recurrence rate. Neuroendocrinology 2011 (E-pub ahead of print).
29. Rindi G, Arnold R, Bosman FT, et al: Nomenclature and classification of neuroendocrine neoplasms of the digestive system; in Bosman FT, et al (eds): WHO Classification of Tumours of the Digestive System. Lyon, IARC Press, 2010, pp 13-14.
30. La Rosa S, Inzani F, Vanoli A, et al: Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol 2011; 42: 1373-1384.
31. Lehy T, Cadiot G, Mignon M, et al: Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut 1992; 33: 1275-1279.
32. Cadiot G, Laurent-Puig P, Thuille B, et al: Is the multiple endocrine neoplasia type 1 gene a suppressor for fundic argyrophil tumors in the Zollinger-Ellison syndrome? Gastroenterology 1993; 105: 579-582. (Pubitemid 23213547)
33. Gibril F, Schumann M, Pace A, et al: Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: A prospective study of 107 cases and comparison with 1,009 cases from the literature. Medicine (Baltimore) 2004; 83: 43-83. (Pubitemid 38124855)
34. Norton JA, Melcher ML, Gibril F, et al: Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery 2004; 136: 1267-1274. (Pubitemid 39647544)
35. Cadiot G, Vissuzaine C, Potet F, et al: Fundic argyrophil carcinoid tumor in a patient with sporadic-type Zollinger-Ellison syndrome. Dig Dis Sci 1995; 40: 1275-1278.
36. Rindi G, Azzoni C, La Rosa S, et al: ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: Prognostic evaluation by pathological analysis. Gastroenterology 1999; 116: 532-542. (Pubitemid 29106760)
37. Modlin IM, Lye KD, Kidd M: Carcinoid tumors of the stomach. Surg Oncol 2003; 12: 153-172. (Pubitemid 37289020)
38. Williams ED, Sandler M: The classification of carcinoid tumours. Lancet 1963; 1: 238-239.
39. Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959. (Pubitemid 36173145)
40. Spinazzola AJ, Gillesby WJ: Primary malignant neoplasms of the duodenum: Report of twelve cases. Am Surg 1963; 29: 405-412.
41. Witzigmann H, Loracher C, Geissler F, Wagner T, Tannapfel A, Uhlmann D, Caca K, Hauss J, Hehl A: Neuroendocrine tumours of the duodenum: Clinical aspects, pathomorphology and therapy. Langenbecks Arch Surg 2002; 386: 525-533. (Pubitemid 34142042)
42. Bornstein-Quevedo L, Gamboa-Dominguez A: Carcinoid tumors of the duodenum and ampulla of Vater: A clinicomorphologic, immunohistochemical, and cell kinetic comparison. Hum Pathol 2001; 32: 1252-1256. (Pubitemid 33107333)
43. Walton GF, Gibbs ER, Spencer GO, Laws HL: Carcinoid tumors of the ampulla of Vater. Am Surg 1997; 63: 302-304. (Pubitemid 27152709)
44. Hatzitheoklitos E, Buchler MW, Friess H, Poch B, Ebert M, Mohr W, et al: Carcinoid of the ampulla of Vater: Clinical characteristics and morphologic features. Cancer 1994; 73: 1580-1588. (Pubitemid 24085256)
45. Clements WM, Martin SP, Stemmerman G, Lowy AM: Ampullary carcinoid tumors: Rationale for an aggressive surgical approach. J Gastrointest Surg 2003; 7: 773-776. (Pubitemid 37103132)
46. Hartel M, Wente MN, Sido B, Friess H, Buchler MW: Carcinoid of the ampulla of Vater. J Gastroenterol Hepatol 2005; 20: 676-681. (Pubitemid 40733359)
47. Soga J, Yakuwa Y: Somatostatinoma/inhibitory syndrome: A statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res 1999; 18: 13-22. (Pubitemid 29232065)
48. Taccagni GL, Carlucci M, Sironi M, Cantaboni A, DiCarlo V: Duodenal somatostatinoma with psammoma bodies: An immunohistochemical and ultrastructural study. Am J Gastroenterol 1986; 81: 33-37. (Pubitemid 16132978)
49. Green BT, Rockey DC: Duodenal somatostatinoma presenting with complete somatostatinoma syndrome. J Clin Gastroenterol 2001; 33: 415-417. (Pubitemid 33026730)
50. Swinburn BA, Yeong ML, Lane MR, Nicholson GI, Holdaway IM: Neurofibromatosis associated with somatostatinoma: A report of two patients. Clin Endocrinol (Oxf) 1988; 28: 353-359.
51. Jensen RT: Endocrine tumors of the pancreas; in Yamada T, Alpers DH, Kaplowitz N, Laine L, Owyang C, Powell DW (eds): Textbook of Gastroenterology. Philadelphia, Lippincott Williams & Wilkins, 2003, pp 2108-2146.
52. Weichert RF 3rd, Roth LM, Krementz ET, Hewitt RL, Drapanas T: Carcinoid-islet cell tumors of the duodenum. Am J Surg 1971; 121: 195-205.
53. Lasson A, Alwmark A, Nobin A, Sundler F: Endocrine tumors of the duodenum. Clinical characteristics and hormone content. Ann Surg 1983; 197: 393-398. (Pubitemid 13112778)
54. Alumets J, Sundler F, Falkmer S, Ljungberg O, Hakanson R, Martensson H, et al: Neurohormonal peptides in endocrine tumors of the pancreas, stomach, and upper small intestine. I. An immunohistochemical study of 27 cases. Ultrastruct Pathol 1983; 5: 55-72. (Pubitemid 14242613)
55. Stamm B, Hedinger CE, Saremaslani P: Duodenal and ampullary carcinoid tumors. A report of 12 cases with pathological characteristics, polypeptide content and relation to MEN-1 syndrome and von Recklinghausen's disease (neurofibromatosis). Virchows Arch A Pathol Anat Histopathol 1986; 408: 475-489. (Pubitemid 16154510)
56. Burke AP, Sobin LH, Federspiel BH, Shekitka KM, Helwig EB: Carcinoid tumors of the duodenum: A clinicopathologic study of 99 cases. Arch Pathol Lab Med 1990; 114: 700-704. (Pubitemid 20207048)
57. Capella C, Riva C, Rindi G, Usellini L, Chiaravalli A, Solcia E: Endocrine tumors of the duodenum and upper jejunum: A study of 33 cases with clinico-pathological characteristics and hormone content. Hepatogastroenterology 1990; 37: 247-252. (Pubitemid 20162267)
58. Heymann MF, Hamy A, Triau S, Miraille E, Toquet C, Chomarat H, Cohen C, Maitre F, Le Bodie MF: Endocrine tumors of the duodenum. A study of 55 cases relative to clinicopathological features and hormone content. Hepatogastroenterology 2004; 51: 1367-1371. (Pubitemid 38987483)
59. Soga J: Endocrinocarcinomas (carcinoids and their variants) of the duodenum. An evaluation of 927 cases. J Exp Clin Cancer Res 2003; 22: 349-363. (Pubitemid 37205391)
60. Thom AK, Norton JA, Axiotis CA, Jensen RT: Location, incidence and malignant potential of duodenal gastrinomas. Surgery 1991; 110: 1086-1093.
61. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Jensen RT: Does the use of routine duodenotomy affect rate of cure, development of liver metastases or survival in patients with Zollinger-Ellison syndrome? Ann Surg 2004; 239: 617-626. (Pubitemid 38525632)
62. Norton JA, Jensen RT: Current surgical management of Zollinger-Ellison syndrome in patients without multiple endocrine neoplasia type 1. Surg Oncol 2003; 12: 145-151. (Pubitemid 37289019)
63. Gibril F, Jensen RT: Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome. Curr Gastroenterol Rep 2005; 7: 114-121. (Pubitemid 40796696)
64. Zogakis TG, Gibril F, Libutti SK, Norton JA, White DE, Jensen RT, Alexander HR: Management and outcome of patients with sporadic gastrinomas arising in the duodenum. Ann Surg 2003; 238: 42-48. (Pubitemid 38176406)
65. Jensen RT, Gardner JD: Gastrinoma; in Go VLW, DiMagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA (eds): The Pancreas: Biology, Pathobiology and Disease. New York, Raven Press, 1993, pp 931-978.
66. Weber HC, Venzon DJ, Lin JT, Fishbein VA, Orbuch M, Strader DB, et al: Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: A prospective long-term study. Gastroenterology 1995; 108: 1637-1649.
67. Yu F, Venzon DJ, Serrano J, Goebel SU, Doppman JL, Gibril F, Jensen RT: Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome. J Clin Oncol 1999; 17: 615-630. (Pubitemid 29075250)
68. Gibril F, Schumann M, Pace A, Jensen RT: Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: A prospective study of 107 cases and comparison with 1,009 patients from the literature. Medicine 2004; 83: 43-83. (Pubitemid 38124855)
69. Jensen RT: Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 1998; 243: 477-488. (Pubitemid 28312244)
70. Norton JA, Fraker DL, Alexander HR, Venzon DJ, Doppman JL, Serrano J, Goebel SU, Peghini P, Roy PK, Gibril F, Jensen RT: Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999; 341: 635-644. (Pubitemid 29399042)
71. Burke AP, Helwig EB: Gangliocytic paraganglioma. Am J Clin Pathol 1985; 92: 1-9. (Pubitemid 19172915)
72. Cohen T, Zweig SJ, Tallis A, Tuazon R, Reich M: Paraganglioneuroma of the duodenum: Report of a case with radiographic findings, angiographic findings and a review of the literature. Am J Gastroenterol 1981; 75: 197-203. (Pubitemid 11113411)
73. Makhlouf HR, Burke AP, Sobin LH: Carcinoid tumors of the ampulla of Vater: A comparison with duodenal carcinoid tumors. Cancer 1999; 85: 1241-1249. (Pubitemid 29125076)
74. Kirshbom PM, Kherani AR, Onaitis MW, Hata A, Kehoe TE, Feldman C, Feldman JM, Tyler DS: Foregut carcinoids: A clinical and biochemical analysis. Surgery 1999; 126: 1105-1110.
75. Zyromski NJ, Kendrick ML, Nagorney DM, Grant CS, Donohue JH, Farnell MB, Thompson GB, Farley DR, Sarr MG: Duodenal carcinoid tumors: How aggressive should we be? J Gastrointest Surg 2001; 5: 588-593. (Pubitemid 33651264)
76. Wang HY, Chen MJ, Yang TL, Chang MC, Chan YJ: Carcinoid tumor of the duodenum and accessory papilla associated with polycythemia vera. World J Gastroenterol 2005; 11: 3794-3796.
77. Amano S, Hazama F, Haebara H, Tsurusawa M, Kaito H: Ectopic ACTH-MSH producing carcinoid tumor with multiple endocrine hyperplasia in a child. Acta Pathol Jpn 1978; 28: 721-730. (Pubitemid 9039643)
78. Dayal Y, Tallberg KA, Nunnemacher G, DeLellis RA, Wolfe HJ: Duodenal carcinoids in patients with and without neurofibromatosis: A comparative study. Am J Surg Pathol 1986; 10: 348-357. (Pubitemid 16038746)
79. Annibale B, Azzoni C, Corleto VD, et al: Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid. Eur J Gastroenterol Hepatol 2001; 13: 1449-1456. (Pubitemid 33151497)
80. Cattan D, Roucayrol AM, Launay JM, et al: Serum gastrin and argyrophil cell hyperplasia relationships in fundic gastritis; in Hankanson R, Sunder F (eds): The Stomach as an Endocrine Organ. Amsterdam, Elsevier Science, 1991, pp 425-448.
81. Borch K, Renvall H, Liedberg G, et al: Relations between circulating gastrin and endocrine cell proliferation in the atrophic gastric fundic mucosa. Scand J Gastroenterol 1986; 21: 357-363. (Pubitemid 16124133)
82. Peracchi M, Gebbia C, Basilisco G, et al: Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur J Endocrinol 2005; 152: 443-448. (Pubitemid 40439498)
83. Lehy T, Mignon M, Cadiot G, et al: Gastric endocrine cell behavior in Zollinger-Ellison patients upon long-term potent antisecretory treatment. Gastroenterology 1989; 96: 1029-1040. (Pubitemid 19091117)
84. Mignon M, Lehy T, Bonnefond A, et al: Development of gastric argyrophil carcinoid tumors in a case of Zollinger-Ellison syndrome with primary hyperparathyroidism during long-term antisecretory treatment. Cancer 1987; 59: 1959-1962. (Pubitemid 17072425)
85. Maton PN, Miller DL, Doppman JL, Collen MJ, Norton JA, Vinayek R, et al: Role of selective angiography in the management of Zollinger-Ellison syndrome. Gastroenterology 1987; 92: 913-918. (Pubitemid 17046307)
86. Mullen JT, Wang H, Yao JC, Lee JH, Perrier ND, Pisters PW, Lee JE, Evans DB: Carcinoid tumors of the duodenum. Surgery 2005; 138: 971-977.
87. Orbuch M, Doppman JL, Strader DB, Fishbeyn VA, Benya RV, Metz DC, Jensen RT: Imaging for pancreatic endocrine tumor localization: Recent advances; in Mignon M, Jensen RT (eds): Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Front Gastrointest Res. Basel, Karger, 1995, vol 23, pp 268-281.
88. Norton JA, Doppman JL, Jensen RT: Curative resection in Zollinger-Ellison syndrome: Results of a 10-year prospective study. Ann Surg 1992; 215: 8-18.
89. Alexander HR, Fraker DL, Norton JA, Barlett DL, Tio L, Benjamin SB, et al: Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 1998; 228: 228-238. (Pubitemid 30191719)
90. Frucht H, Doppman JL, Norton JA, Miller DL, Dwyer AJ, Frank JA, et al: Gastrinomas: Comparison of MR Imaging with CT, angiography and US. Radiology 1989; 171: 713-717.
91. Gibril F, Jensen RT: Diagnostic uses of radiolabelled somatostatin-receptor analogues in gastroenteropancreatic endocrine tumors. Dig Liver Dis 2004; 36:S106-S120. (Pubitemid 41115498)
92. Acs G, McGrath CM, Gupta PK: Duodenal carcinoid tumor: Report of a case diagnosed by endoscopic ultrasound-guided fine-needle aspiration biopsy with immunocytochemical correlation. Diagn Cytopathol 2000; 23: 183-186. (Pubitemid 30660423)
93. Yoshikane H, Tsukamoto Y, Niwa Y, Goto H, Hase S, Mizutani K, Nakamura T: Carcinoid tumors of the gastrointestinal tract: Evaluation with endoscopic ultrasonography. Gastrointest Endosc 1993; 39: 375-383. (Pubitemid 23159092)
94. Dalenback J, Havel G: Local endoscopic removal of duodenal carcinoid tumors. Endoscopy 2004; 36: 651-655. (Pubitemid 38979162)
95. Yoshikane H, Suzuki T, Yoshioka N, Ogawa Y, Hamajima E, Hasegawa N, Hasegawa C: Duodenal carcinoid tumor: Endosonographic imaging and endoscopic resection. Am J Gastroenterol 1995; 90: 642-644.
96. Yoshikane H, Goto H, Niwa Y, Matsui M, Ohashi S, Suzuki T, et al: Endoscopic resection of small duodenal carcinoid tumors with strip biopsy technique. Gastrointest Endosc 1998; 47: 466-470. (Pubitemid 28287564)
97. Norton JA, Jensen RT: Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 2004; 240: 757-773. (Pubitemid 39425767)
98. Proye C, Malvaux P, Pattou F, Filoche B, Godchaux JM, Maunoury V, et al: Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy. Surgery 1998; 124: 1134-1144. (Pubitemid 28555206)
99. Ruszniewski P, Amouyal P, Amouyal G, Grange JD, Mignon M, Bouch O, Bernades P: Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. Surgery 1995; 117: 629-635.
100. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, et al: Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: A prospective study. Ann Intern Med 1996; 125: 26-34.
101. Termanini B, Gibril F, Reynolds JC, Doppman JL, Chen CC, Stewart CA, et al: Value of somatostatin receptor scintigraphy: A prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997; 112: 335-347. (Pubitemid 27078820)
102. Gibril F, Doppman JL, Reynolds JC, Chen CC, Sutliff VE, Yu F, et al: Bone metastases in patients with gastrinomas: A prospective study of bone scanning, somatostatin receptor scanning, and MRI in their detection, their frequency, location and effect of their detection on management. J Clin Oncol 1998; 16: 1040-1053. (Pubitemid 28108739)
103. Meijer WG, van der Veer E, Jager PL, van der Jagt EJ, Piers BA, Kema IP, et al: Bone metastases in carcinoid tumors: Clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med 2003; 44: 184-191.
104. Lebtahi R, Cadiot G, Delahaye N, Genin R, Daou D, Peker MC, Chosidow D, Faraggi M, Mignon M, LeGuludec D: Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: Bone scintigraphy compared with somatostatin receptor scintigraphy. J Nucl Med 1999; 40: 1602-1608. (Pubitemid 29471148)
105. Hubalewska-Dydejczyk A, Szybinski P, Fross-Baron K, Mikolajczak R, Huszno B, Sowa-Staszczak A: 99m Tc-EDDA/HYNICoctreotate: A new radiotracer for detection and staging of NET. A case of metastatic duodenal carcinoid. Nucl Med Rev Cent East Eur 2005; 8: 155-156. (Pubitemid 43115971)
106. Taal BG, Smits M: Developments in diagnosis and treatment of metastatic midgut carcinoid tumors: A review. Minerva Gastroenterol Dietol 2005; 51: 335-344. (Pubitemid 43010444)
107. Oo TH, Aish LS, Schneider D, Hassoun H: Carcinoid tumor presenting with bone marrow metastases. J Clin Oncol 2003; 21: 2995-2996.
108. Zuetenhorst JM, Hoefnageli CA, Boot H, Valdes Olmos RA, Taal BG: Evaluation of 111 In-pentetreotide, 131 I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun 2002; 23: 735-741. (Pubitemid 34837003)
109. Goebel SU, Serrano J, Yu F, Gibril F, Venzon DJ, Jensen RT: Prospective study of the value of serum chromogranin A or serum gastrin levels in assessment of the presence, extent, or growth of gastrinomas. Cancer 1999; 85: 1470-1483. (Pubitemid 29152818)
110. Nikou GC, Toubanakis C, Nikolaou P, Giannatou E, Marinou K, Safioleas M, Karamanolis D: Gastrinomas associated with MEN-1 syndrome: New insights for the diagnosis and management in a series of 11 patients. Hepatogastroenterology 2005; 52: 1668-1676. (Pubitemid 41745608)
111. Solcia E, Kloppel G, Sobin LH: Histological typing of endocrine tumours; in Solcia E, Kloppel G, Sobin LH (eds): Histological Typing of Endocrine Tumours. International classification of Tumours, ed 2. Berlin, Springer, 2000.
112. Tanaka S, Yamasaki S, Matsushita S, Ozawa Y, Kurosaki A, Takeuchi K, Hoshihara Y, Doi T, Watanabe G, Kawaminami K: Duodenal somatostatinoma: A case report and review of 31 cases with special reference to the relationship between tumor size and metastasis. Pathol Int 2000; 50: 146-152. (Pubitemid 30253285)
113. Barbareschi M, Frigo B, Aldovini D, Leonardi E, Cristina S, Falleni M: Duodenal gangliocytic paraganglioma. Report of a case and review of the literature. Virchows Arch A Pathol Anat Histopathol 1989; 416: 81-89. (Pubitemid 19252172)
114. Altavilla G, Chiarelli S, Fassina A: Duodenal periampullary gangliocytic paraganglioma: Report of two cases with immunohistochemical and ultrastructural study. Ultrastruct Pathol 2001; 25: 137-145. (Pubitemid 32493526)
115. Sata N, Tsukahara M, Koizumi M, Yoshizawa K, Kurihara K, Nagai H, Someya T, Saito K: Primary small-cell neuroendocrine carcinoma of the duodenum: A case report and review of literature. World J Surg Oncol 2004; 2: 28.
116. Scherübl H, Cadiot G, Jensen RT, et al: Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: Small tumors, small problems? Endoscopy 2010; 42: 664-671.
117. Manfredi S, Pagenaulta M, de Lajarte-Thirouardb AS, et al: Type 1 and 2 gastric carcinoid tumors: Long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue. Eur J Gastroenterol Hepatol 2007; 19: 1021-1025. (Pubitemid 350287412)
118. Grozinsky-Glasberg S, Kaltsas G, Gur C, et al: Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol 2008; 159: 475-482.
119. Campana D, Nori F, Pezzilli R, et al: Gastric endocrine tumors type I: Treatment with long-acting somatostatin analogs. Endocr Relat Cancer 2008; 15: 337-342. (Pubitemid 351449751)
120. Pyun DK, Moon G, Han J, Kim MH, Lee SS, Seo DW, Lee SK: A carcinoid tumor of the ampulla of Vater treated by endoscopic snare papillectomy. Korean J Intern Med 2004; 19: 257-260. (Pubitemid 41237461)
121. Bowers SP, Smith CD: Laparoscopic resection of posterior duodenal bulb carcinoid tumor. Am Surg 2003; 69: 792-795.
122. Perng CL, Lin HJ, Wang K, Lai CR, Lee SD: Treatment of duodenal carcinoid by strip biopsy. J Clin Gastroenterol 1995; 20: 168-171.
123. Sato T, Fukunaga T, Ohyama S, Ueno M, Oya M, Yamamoto J, et al: Endoscopic total layer resection with laparoscopic sentinel node dissection and defect closure for duodenal carcinoid. Hepatogastroenterology 2005; 52: 678-679. (Pubitemid 40834580)
124. Horsley GW, Golden BN: Carcinoid tumors of the duodenum. Surg Gynecol Obstet 1957; 105: 417-424.
125. Thompson GB, Van Heerden JA, Martin JK Jr, Schutt AJ, Ilstrup DM, Carney JA: Carcinoid tumors of the gastrointestinal tract: Presentation, management, and prognosis. Surgery 1985; 98: 1054-1063. (Pubitemid 16104724)
126. Toyonaga T, Nakamura K, Araki Y, Shimura H, Tanaka M: Laparoscopic treatment of duodenal carcinoid tumor: Wedge resection of the duodenal bulb under endoscopic control. Surg Endosc 1998; 12: 1085-1087. (Pubitemid 128531438)
127. Blanc P, Porcheron J, Pages A, Breton C, Mosnier JF, Balique JG: Laparoscopic excision of a duodenal neuroendocrine tumor. Ann Chir 2000; 125: 176-178. (Pubitemid 30219769)
128. Yamamoto C, Aoyagi K, Suekane H, Iida M, Hizawa K, Kuwano Y, et al: Carcinoid tumors of the duodenum: Report of three cases treated by endoscopic resection. Endoscopy 1997; 29: 218-221. (Pubitemid 27268190)
129. Sugg SL, Norton JA, Fraker DL, Metz DC, Pisegna JR, Fishbeyn V, et al: A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Ann Surg 1993; 218: 138-144. (Pubitemid 23229139)
130. Norton JA, Doppman JL, Collen MJ, Harmon JW, Maton PN, Gardner JD, Jensen RT: Prospective study of gastrinoma localization and resection in patients with Zollinger-Ellison syndrome. Ann Surg 1986; 204: 468-479. (Pubitemid 16025363)
131. Yoshikane H, Tsukamoto Y, Niwa Y, Goto H, Hase S, Mizutani K, Nakamura T: Carcinoid tumors of the gastrointestinal tract: Evaluation with endoscopic ultrasonography. Gastrointest Endosc 1993; 39: 375-383. (Pubitemid 23159092)
132. Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, de Jong M: Peptide receptor radionuclide therapy. Ann NY Acad Sci 2004; 1014: 234-245. (Pubitemid 38594811)
133. De Jong M, Kwekkeboom D, Valkema R, Krenning EP: Radiolabelled peptides for tumour therapy: Current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging 2003; 30: 463-469. (Pubitemid 36692876)
134. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al: Overview of results of peptide receptor radionuclide therapy with three radiolabeled somatostatin analogs. J Nucl Med 2005; 46(suppl 1):62S-66S. (Pubitemid 47619020)
135. Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, et al: Survival and response after peptide receptor radionuclide therapy with ( 90 Y-DOTA 0 ,Tyr 3 )octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006; 36: 147-156. (Pubitemid 43320450)
136. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al: Radiolabeled somatostatin analog ( 177 Lu-DOTA 0 ,Tyr 3 )octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23: 2754-2762. (Pubitemid 46179465)
137. Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, et al: ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012;95: 157-176.
138. Modlin IM, Pavel M, Kidd M, et al: Review article: Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010; 31: 169-188.
139. Arnold R, Rinke A, Klose KJ, Muller HH, Wied M, Zamzow K, et al: Octreotide versus octreotide plus interferon in endocrine gastroenteropancreatic tumors: A randomized trial. Clin Gastroenterol Hepatol 2005; 3: 761-771. (Pubitemid 41116728)
140. Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, et al: International Lanreotide and Interferon Alfa Study Group: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors -the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21: 2689-2696. (Pubitemid 46606312)
141. Butturini G, Bettini R, Missiaglia E, Mantovani W, Dalai I, Capelli P, et al: Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer 2006; 13: 1213-1221. (Pubitemid 46212575)